Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
Phase 1
1(25.0%)
Phase 4
1(25.0%)
4Total
Phase 3(2)
Phase 1(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02106572Phase 3Active Not Recruiting

Therapeutic Instillation of Mistletoe

Role: lead

NCT02007005Phase 1Completed

Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

Role: lead

NCT02191540Phase 3Completed

Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients

Role: collaborator

NCT01401075Phase 4Completed

RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients

Role: lead

All 4 trials loaded